製品番号: HY-132191

Pradimicin A

Pradimicin A is a potent antifungal agent with a minimum inhibitory concentration (MIC) of 4 μg/mL against Candida rugosa. Pradimicin A exhibits antiviral activity against SARS-CoV, human immunodeficiency virus (HIV) and other enveloped viruses. Pradimicin A exerts its fungicidal activity through a Ca²⁺-dependent mechanism, which induces fungal lysis. Pradimicin A can be used in research related to fungal infections, HIV infections and COVID-19.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 117704-65-1
分子式: C₄₀H₄₄N₂O₁₈
分子量:840.78

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (277 KB)

Pradimicin A 構造式

CAS 番号: 117704-65-1

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
化学情報
プロトコル (2)
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

^[1]

HIV

HIV アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
C8166	CC₅₀	>50 μM Compound: PRM-A	Cytotoxicity against human C8166 cells after 3 to 4 days Cytotoxicity against human C8166 cells after 3 to 4 days	[PMID: 20047920]
C8166	EC₅₀	2.6 μM Compound: PRM-A	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis	[PMID: 20047920]
Caco-2	CC₅₀	>50 μM Compound: PRM-A	Cytotoxicity against human Caco2 cells after 3 to 4 days Cytotoxicity against human Caco2 cells after 3 to 4 days	[PMID: 20047920]
CCRF-CEM	CC₅₀	>100 μM Compound: Pradimicin A	Cytotoxicity against human CEM cells assessed as cell count after 3 days Cytotoxicity against human CEM cells assessed as cell count after 3 days	[PMID: 26513643]
CCRF-CEM	CC₅₀	>100 μM Compound: PRM-A	Cytotoxicity against human CEM cells after 7 days by trypan blue staining Cytotoxicity against human CEM cells after 7 days by trypan blue staining	[PMID: 20047920]
CCRF-CEM	CC₅₀	>100 μM Compound: Pradimicin	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation	[PMID: 25617695]
CCRF-CEM	CC₅₀	>50 μM Compound: PRM-A	Cytotoxicity against human CD4+ T-lymphocyte CEM cells Cytotoxicity against human CD4+ T-lymphocyte CEM cells	[PMID: 26540494]
CCRF-CEM	EC₅₀	>50 μM Compound: PRM-A	Antiviral activity against HIV-1 3B harboring wild type gp120 infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis Antiviral activity against HIV-1 3B harboring wild type gp120 infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis	[PMID: 20047920]
CCRF-CEM	EC₅₀	>50 μM Compound: PRM-A	Cytotoxicity against human CEM cells after 4 days by by Coulter counter analysis Cytotoxicity against human CEM cells after 4 days by by Coulter counter analysis	[PMID: 21749165]
CCRF-CEM	EC₅₀	3.3 μM Compound: Pradimicin	Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay	[PMID: 25617695]
CCRF-CEM	EC₅₀	3.3 μM Compound: Pradimicin A	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis	[PMID: 26513643]
CCRF-CEM	EC₅₀	3.4 μM Compound: PRM-A	Antiviral activity against HIV1 3B infected in human CD4+ T-lymphocyte CEM cells assessed as inhibition of virus-induced cytopathicity after 4 to 5 days by microscopic analysis Antiviral activity against HIV1 3B infected in human CD4+ T-lymphocyte CEM cells assessed as inhibition of virus-induced cytopathicity after 4 to 5 days by microscopic analysis	[PMID: 26540494]
CCRF-CEM	EC₅₀	4.3 μM Compound: PRM-A	Antiviral activity against SIV mac251 infected in human HUT78 cells assessed as prevention of syncytium formation between persistently SIV mac251-infected HUT-78 cells and uninfected CEM cells after 3 to 4 days by ELISA Antiviral activity against SIV mac251 infected in human HUT78 cells assessed as prevention of syncytium formation between persistently SIV mac251-infected HUT-78 cells and uninfected CEM cells after 3 to 4 days by ELISA	[PMID: 20047920]
CCRF-CEM	EC₅₀	5.2 μM Compound: PRM-A	Antiviral activity against compound pretreated HIV-1 3B isolate 42 harboring gp120 mutant infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis Antiviral activity against compound pretreated HIV-1 3B isolate 42 harboring gp120 mutant infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis	[PMID: 20047920]
CCRF-CEM	EC₅₀	5.2 μM Compound: PRM-A	Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis	[PMID: 20047920]
CCRF-CEM	EC₅₀	5.2 μM Compound: PRM-A	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 21749165]
CCRF-CEM	EC₅₀	5.9 μM Compound: Pradimicin	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay	[PMID: 25617695]
CCRF-CEM	EC₅₀	5.9 μM Compound: Pradimicin A	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis	[PMID: 26513643]
CCRF-CEM	EC₅₀	5.9 μM Compound: PRM-A	Antiviral activity against HIV-1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis Antiviral activity against HIV-1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis	[PMID: 20047920]
CCRF-CEM	EC₅₀	5.9 μM Compound: PRM-A	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 21749165]
HeLa	CC₅₀	>50 μM Compound: PRM-A	Cytotoxicity against human HeLa cells after 3 to 4 days Cytotoxicity against human HeLa cells after 3 to 4 days	[PMID: 20047920]
L1210	CC₅₀	>50 μM Compound: PRM-A	Cytotoxicity against mouse L1210 cells after 3 to 4 days Cytotoxicity against mouse L1210 cells after 3 to 4 days	[PMID: 20047920]
MOLT-4	CC₅₀	>50 μM Compound: PRM-A	Cytotoxicity against human Molt4 cells after 3 to 4 days Cytotoxicity against human Molt4 cells after 3 to 4 days	[PMID: 20047920]
MT4	CC₅₀	>100 μM Compound: PRM-A	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTS/PES assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTS/PES assay	[PMID: 31809045]
MT4	CC₅₀	>100 μM Compound: PRM-A	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTS/PES assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTS/PES assay	[PMID: 34229438]
MT4	CC₅₀	>100 μM Compound: PRM-A	Cytotoxicity against human MT4 cells assessed as cell viability measured after 5 days by MTS assay Cytotoxicity against human MT4 cells assessed as cell viability measured after 5 days by MTS assay	[PMID: 35512567]
MT4	CC₅₀	>50 μM Compound: PRM-A	Cytotoxicity against human MT4 cells after 7 days by trypan blue staining Cytotoxicity against human MT4 cells after 7 days by trypan blue staining	[PMID: 20047920]
MT4	EC₅₀	5 μM Compound: PRM-A	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining	[PMID: 20047920]
MT4	EC₅₀	5.2 μM Compound: PRM-A	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining	[PMID: 20047920]
MT4	EC₅₀	5.5 μM Compound: PRM-A	Antiviral activity against SIV mac251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining Antiviral activity against SIV mac251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining	[PMID: 20047920]
OST	CC₅₀	>50 μM Compound: PRM-A	Cytotoxicity against human thymidine kinase-negative OST cells after 3 to 4 days Cytotoxicity against human thymidine kinase-negative OST cells after 3 to 4 days	[PMID: 20047920]
PBMC	CC₅₀	>250 μM Compound: PRM-A	Cytotoxicity against human PBMC after 7 days by trypan blue staining Cytotoxicity against human PBMC after 7 days by trypan blue staining	[PMID: 20047920]
PBMC	CC₅₀	>50 μM Compound: PRM-A	Cytotoxicity against human PBMC cells after 3 to 4 days Cytotoxicity against human PBMC cells after 3 to 4 days	[PMID: 20047920]
PBMC	EC₅₀	>50 μM Compound: PRM-A	Antiviral activity against HIV-1 3B cells infected in human PBMC cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis Antiviral activity against HIV-1 3B cells infected in human PBMC cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis	[PMID: 20047920]
Raji	EC₅₀	3.4 μM Compound: PRM-A	Antiviral activity against compound pretreated X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 4 Antiviral activity against compound pretreated X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 4	[PMID: 20047920]
Raji	EC₅₀	5.4 μM Compound: PRM-A	Antiviral activity against X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 36 to 42 hrs by micro Antiviral activity against X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 36 to 42 hrs by micro	[PMID: 20047920]
Raji	IC₅₀	16 μM Compound: PRM-A	Antiviral activity against SIV mac251 infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA Antiviral activity against SIV mac251 infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA	[PMID: 20047920]
Raji	IC₅₀	16 μM Compound: PRM-A	Antiviral activity against SIV mac251 infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 60 mins by ELISA Antiviral activity against SIV mac251 infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 60 mins by ELISA	[PMID: 20047920]
Raji	IC₅₀	21 μM Compound: PRM-A	Antiviral activity against R5 tropic HIV-1 Bal infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA Antiviral activity against R5 tropic HIV-1 Bal infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA	[PMID: 20047920]
Raji	IC₅₀	3.5 μM Compound: PRM-A	Antiviral activity against X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA Antiviral activity against X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA	[PMID: 20047920]
SUP-T1	EC₅₀	3.4 μM Compound: PRM-A	Antiviral activity against HIV-1 3B infected in human HUT78 cells assessed as prevention of syncytium formation between persistently HIV-1 3B-infected HUT-78 cells and uninfected SupT1 cells after 3 to 4 days by ELISA Antiviral activity against HIV-1 3B infected in human HUT78 cells assessed as prevention of syncytium formation between persistently HIV-1 3B-infected HUT-78 cells and uninfected SupT1 cells after 3 to 4 days by ELISA	[PMID: 20047920]
U-87MG ATCC	CC₅₀	>50 μM Compound: PRM-A	Cytotoxicity against human U87 cells after 3 to 4 days Cytotoxicity against human U87 cells after 3 to 4 days	[PMID: 20047920]

体外実験

Pradimicin A (48 h) inhibits the growth of Candida rugosa with a minimum inhibitory concentration (MIC) of 4 μg/mL, and completely inhibits Candida rugosa growth while showing preferential binding to branched oligomannose motifs 6 and 7 (MAC = 1 mM) relative to other tested glycan structures^[1]^[3].
Pradimicin A (0.3-100 μM; 1 h pre-incubation, 3 days post challenge) inhibits SARS-CoV-2 infection of Calu-3 cells with an IC₅₀ of 1.2 μM, shows no cytotoxicity at concentrations up to 100 μM, and its antiviral activity is dependent on binding to branched oligomannose motifs on viral spike proteins^[1].
Pradimicin A (1 mM) shows Ca²⁺‑dependent specific binding to Man-OMe (100 mM) with two distinct binding sites in ITC assays (40 injections, 30 °C). The primary binding (K_a = 10400 M⁻¹) is approximately 40‑fold stronger than the secondary binding (K_a = 263 M⁻¹)^[2].
Pradimicin A (1 mM) binds methyl α-D-mannopyranoside in a cell-free buffer system with a primary dissociation constant (K_d1) of 96 μM and a secondary dissociation constant (K_d2) of 3800 μM^[3].
Pradimicin A (0.8-12.5 μg/mL) exhibits broad-spectrum antifungal activity against diverse fungal species including Candida albicans A9540^[5].
Pradimicin A exhibits antiviral activity against coronaviruses and HIV-1, targeting viral glycoprotein mannose moieties and demonstrating a high genetic barrier to HIV-1 resistance^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

化学情報

CAS 番号 117704-65-1
分子量 840.78
分子式 C₄₀H₄₄N₂O₁₈
SMILES

OC1=C2C3=C(O)C(C(N[C@H](C)C(O)=O)=O)=C(C)C=C3[C@@H]([C@H](C2=CC4=C1C(C5=CC(OC)=CC(O)=C5C4=O)=O)O)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)C)NC)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O)O
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

プロトコル

All Signal Pathway Related Cell Biology

Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Ca²⁺ Staining Technique
Ca²⁺ staining is an experimental technique that utilizes specific fluorescent probes (such as Fluo-4 AM, Fura-2, etc.) to qualitatively or quantitatively detect dynamic changes in intracellular Ca²⁺ concentrations; this is achieved by monitoring the changes in fluorescent signals generated when these probes bind to free intracellular calcium ions. The underlying principle relies primarily on the presence of chelating groups within the probe's molecular structure that possess high affinity for calcium ions.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (277 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Nakagawa Y, et al. Molecular basis of N-glycan recognition by pradimicin a and its potential as a SARS-CoV-2 entry inhibitor. Bioorg Med Chem. 2024 May 1;105:117732. [Content Brief]

[2]. Nakagawa Y, et al. Mapping of the primary mannose binding site of pradimicin A. J Am Chem Soc. 2011;133(43):17485-17493. [Content Brief]

[3]. Miyanishi W, et al. d-Mannose binding, aggregation property, and antifungal activity of amide derivatives of pradimicin A. Bioorg Med Chem. 2022;55:116590. [Content Brief]

[4]. Nakagawa Y, et al. Molecular Basis of Mannose Recognition by Pradimicins and their Application to Microbial Cell Surface Imaging. Cell Chem Biol. 2019;26(7):950-959.e8. [Content Brief]

[5]. Guo Y, et al. Isolation, biosynthesis, and biological activity of pradimicins from actinomycetes. Bioorg Chem. 2025;164:108884. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Pradimicin A

HIV アイソフォーム固有の製品をすべて表示

生物活性

製品説明

IC₅₀ & Target

Cellular Effect

体外実験

化学情報

プロトコル

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

Bioz

Keywords

最近チェックした製品

Pradimicin A

HIV アイソフォーム固有の製品をすべて表示

生物活性

製品説明

IC50 & Target

Cellular Effect

体外実験

化学情報

プロトコル

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

Pradimicin A 関連分類

HY-132191 関連分類

Bioz

Keywords

最近チェックした製品

IC₅₀ & Target